Infectious Disease Market is estimated to increase at a growth rate of 5.8% CAGR over the forecast period from 2024 to 2030.
The global Infectious Disease Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Drugs, Vaccines), By End-User (Hospital, Multispecialty clinic, Others).
An Introduction to Infectious Disease Market in 2024
The Infectious Disease Market encompasses a broad spectrum of diseases caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites, posing significant public health challenges globally. This market includes diagnostics, vaccines, antiviral drugs, antibiotics, and therapeutics used for preventing, diagnosing, and treating infectious diseases like influenza, HIV/AIDS, tuberculosis, malaria, COVID-19, and emerging infectious threats. Innovations in infectious disease management focus on rapid diagnostics, surveillance systems, antimicrobial stewardship, vaccination strategies, and novel therapies to combat drug resistance, control outbreaks, and improve infectious disease control and prevention efforts worldwide.
Infectious Disease Market Competitive Landscape
The global Infectious Disease Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Infectious Disease Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Infectious Disease Industry include- Abbott Laboratories, Becton Dickinson and Co., bioMerieux SA, Danaher Corp, DiaSorin SpA, F. Hoffmann La Roche Ltd, Genetic Signatures Ltd, Grifols S.A., Hologic Inc, Meridian Bioscience Inc, Meril Life Sciences Pvt. Ltd, OraSure Technologies Inc, PerkinElmer Inc, QIAGEN N.V., Quidel Corp, Rad Laboratories Inc, Siemens AG, Sysmex Corp, Thermo Fisher Scientific Inc, Trinity Biotech Plc.
Infectious Disease Market Trend: Emergence of Novel Infectious Agents and Pandemic Preparedness
A significant trend in the Infectious Disease market is the emergence of novel infectious agents, such as coronaviruses, influenza viruses, and antibiotic-resistant bacteria, along with heightened awareness and preparedness for pandemics. Recent outbreaks, including the COVID-19 pandemic, have underscored the importance of proactive surveillance, rapid diagnostics, and effective response strategies to mitigate the spread of infectious diseases and minimize their impact on public health and global economies. This trend drives investments in research and development of vaccines, therapeutics, diagnostic tests, and public health interventions to address emerging infectious threats and strengthen pandemic preparedness efforts worldwide.
Infectious Disease Market Driver: Globalization, Urbanization, and Climate Change
The market is primarily driven by globalization, urbanization, and climate change, which contribute to the increased transmission and spread of infectious diseases across geographic boundaries. Factors such as international travel, population density, deforestation, and changing environmental conditions create favorable conditions for the emergence and dissemination of infectious agents, posing significant challenges to disease control and containment efforts. Additionally, socio-economic disparities, inadequate healthcare infrastructure, and population displacement exacerbate vulnerability to infectious diseases, driving the need for sustainable interventions and collaborative approaches to address infectious disease threats effectively.
Infectious Disease Market Opportunity: Innovation in Antimicrobial Therapeutics and Diagnostics
An opportunity in the Infectious Disease market lies in innovation in antimicrobial therapeutics and diagnostics to combat antimicrobial resistance (AMR) and improve infectious disease management. With the rise of multidrug-resistant pathogens and the dwindling pipeline of new antibiotics, there is an urgent need to develop novel antimicrobial agents, alternative treatment modalities, and diagnostic tools that can accurately identify drug-resistant strains, guide antimicrobial therapy decisions, and optimize patient outcomes. Additionally, there is potential for investment in research and development of vaccines, prophylactic measures, and public health interventions that target high-burden infectious diseases, such as tuberculosis, malaria, HIV/AIDS, and neglected tropical diseases, to reduce morbidity, mortality, and transmission rates, thus contributing to sustainable infectious disease control and global health security.
Infectious Disease Market Share Analysis: Vaccines is the fastest growing market segment over the forecast period to 2030
In the realm of Infectious Disease management, the segment experiencing the most rapid growth is Vaccines. Vaccines are crucial in preventing the spread of infectious diseases by stimulating the immune system to develop immunity against specific pathogens. With the continuous emergence of new infectious diseases and the reemergence of previously controlled ones, there has been an increasing emphasis on vaccination as a primary preventive measure. Governments, healthcare organizations, and individuals worldwide are prioritizing vaccination campaigns to curb the spread of infectious diseases and protect public health. Moreover, advancements in vaccine technology, including the development of novel platforms such as mRNA vaccines, are driving innovation and expanding the range of diseases that can be targeted by vaccination. As a result, the vaccines segment is witnessing significant growth, fueled by the growing demand for preventive healthcare solutions and the imperative to combat infectious diseases effectively.
Infectious Disease Market Segmentation
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Infectious Disease Companies
Abbott Laboratories
Becton Dickinson and Co.
bioMerieux SA
Danaher Corp
DiaSorin SpA
F. Hoffmann La Roche Ltd
Genetic Signatures Ltd
Grifols S.A.
Hologic Inc
Meridian Bioscience Inc
Meril Life Sciences Pvt. Ltd
OraSure Technologies Inc
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
Rad Laboratories Inc
Siemens AG
Sysmex Corp
Thermo Fisher Scientific Inc
Trinity Biotech Plc
* List not Exhaustive
Reasons to Buy the Infectious Disease Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Infectious Disease Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Infectious Disease Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Infectious Disease Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Infectious Disease Market Size Outlook, $ Million, 2021 to 2030
3.2 Infectious Disease Market Outlook by Type, $ Million, 2021 to 2030
3.3 Infectious Disease Market Outlook by Product, $ Million, 2021 to 2030
3.4 Infectious Disease Market Outlook by Application, $ Million, 2021 to 2030
3.5 Infectious Disease Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Infectious Disease Industry
4.2 Key Market Trends in Infectious Disease Industry
4.3 Potential Opportunities in Infectious Disease Industry
4.4 Key Challenges in Infectious Disease Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Infectious Disease Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Infectious Disease Market Outlook by Segments
7.1 Infectious Disease Market Outlook by Segments, $ Million, 2021- 2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
8 North America Infectious Disease Market Analysis and Outlook To 2030
8.1 Introduction to North America Infectious Disease Markets in 2024
8.2 North America Infectious Disease Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Infectious Disease Market size Outlook by Segments, 2021-2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
9 Europe Infectious Disease Market Analysis and Outlook To 2030
9.1 Introduction to Europe Infectious Disease Markets in 2024
9.2 Europe Infectious Disease Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Infectious Disease Market Size Outlook by Segments, 2021-2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
10 Asia Pacific Infectious Disease Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Infectious Disease Markets in 2024
10.2 Asia Pacific Infectious Disease Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Infectious Disease Market size Outlook by Segments, 2021-2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
11 South America Infectious Disease Market Analysis and Outlook To 2030
11.1 Introduction to South America Infectious Disease Markets in 2024
11.2 South America Infectious Disease Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Infectious Disease Market size Outlook by Segments, 2021-2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
12 Middle East and Africa Infectious Disease Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Infectious Disease Markets in 2024
12.2 Middle East and Africa Infectious Disease Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Infectious Disease Market size Outlook by Segments, 2021-2030
By Product
Drugs
Vaccines
By End-User
Hospital
Multispecialty clinic
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Becton Dickinson and Co.
bioMerieux SA
Danaher Corp
DiaSorin SpA
F. Hoffmann La Roche Ltd
Genetic Signatures Ltd
Grifols S.A.
Hologic Inc
Meridian Bioscience Inc
Meril Life Sciences Pvt. Ltd
OraSure Technologies Inc
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
Rad Laboratories Inc
Siemens AG
Sysmex Corp
Thermo Fisher Scientific Inc
Trinity Biotech Plc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
